Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.

The proteasome inhibitor bortezomib (Velcade) was recently approved for the treatment of therapy-refractive multiple myeloma and is under investigation for numerous other types of cancer. A phase I clinical trial in paediatric patients resulted in tolerable toxicity. Since the emergence of chemoresistance represents one of the major drawbacks in cancer therapy, we investigated the influence of bortezomib on multi-drug resistant human neuroblastoma cell lines characterised by P-glycoprotein expression and p53 mutation. Nanomolar concentrations of bortezomib inhibited the cell cycle and induced apoptosis in chemosensitive as well as in chemoresistant cell lines. In vivo growth of chemosensitive and chemoresistant neuroblastoma cell lines was inhibited to a similar extent. In addition, bortezomib inhibited vessel formation in neuroblastoma xenografts. These findings and the favourable toxicity profile of bortezomib in children make it reasonable to further pursue additional development of the drug for the treatment of neuroblastoma and other paediatric solid tumours.

[1]  Tak W. Mak,et al.  Pathways of apoptotic and non-apoptotic death in tumour cells , 2004, Nature Reviews Cancer.

[2]  Y. Sakamoto,et al.  Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice , 2004, Cancer science.

[3]  G. Morgan,et al.  Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy , 2005, Cancer Cell International.

[4]  S. Groshen,et al.  Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. , 1998, Cancer research.

[5]  K. Black,et al.  Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM) , 2005, Oncogene.

[6]  P. Richardson,et al.  Proteasome Inhibition in the Treatment of Cancer , 2005, Cell cycle.

[7]  S. Cohn,et al.  Advances in the diagnosis and treatment of neuroblastoma. , 2003, The oncologist.

[8]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[9]  P. Elliott,et al.  Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. LaQuaglia,et al.  Multidrug resistance in human neuroblastoma cells. , 1991, Journal of pediatric surgery.

[11]  Michael L. Wang,et al.  Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Blaheta,et al.  Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model , 2003, International journal of cancer.

[13]  J. Lunec,et al.  Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. , 2001, Cancer research.

[14]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[15]  J. Cinatl,et al.  Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs. , 2000, Anticancer Research.

[16]  Ann Richmond,et al.  Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition , 2004, Cancer Research.

[17]  M. Michaelis,et al.  Treatment of drug-resistant human neuroblastoma cells with cyclodextrin inclusion complexes of aphidicolin , 2001, Anti-cancer drugs.

[18]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[19]  P. Elliott,et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.

[20]  P. Richardson,et al.  Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[22]  D. Frappaz,et al.  Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Logothetis,et al.  Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. , 2003, Molecular cancer therapeutics.

[24]  A. Zelenetz,et al.  Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Elliott,et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer , 2001, Journal of cellular biochemistry.

[26]  G. Dbaibo,et al.  Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma , 2005, Oncogene.

[27]  T. Wheldon,et al.  A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. , 1995, Cancer research.

[28]  M. Matsuoka,et al.  Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro , 2004, Leukemia.

[29]  Jian Yu,et al.  Differential Apoptotic Response to the Proteasome Inhibitor Bortezomib (VELCADETM, PS-341) in Bax-Deficient and p21-Deficient Colon Cancer Cells , 2003, Cancer biology & therapy.

[30]  D. McConkey,et al.  The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. , 2003, Cancer research.

[31]  L. Attardi,et al.  The role of apoptosis in cancer development and treatment response , 2005, Nature Reviews Cancer.

[32]  I. Fichtner,et al.  Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. , 2004, European journal of cancer.

[33]  A. von Deimling,et al.  Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. , 2005, International journal of oncology.

[34]  E. White,et al.  Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. , 2005, Cancer cell.

[35]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[36]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[37]  M. Michaelis,et al.  Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. , 2004, International journal of oncology.

[38]  J. Adams.  The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.

[39]  K. Neville,et al.  Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Vogel,et al.  Bovine seminal ribonuclease selectively kills human multidrug-resistant neuroblastoma cells via induction of apoptosis. , 1999, International journal of oncology.

[41]  Z Chen,et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  J. Lunec,et al.  The p53 pathway and its inactivation in neuroblastoma. , 2003, Cancer letters.

[43]  R. Herbst,et al.  The proteasome inhibitor PS-341 in cancer therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.